Journal Article Review Epublish
PubMed: 40821797 DOI: 10.3389/fimmu.2025.1593885
COVID-19: a vascular nightmare unfolding.
Front Immunol 16:1593885
Authors: Qinan Yin, Youjin Huang, Hulin Wang, Yin Wang, Xuefei Huang, Yujie Song, Yueyuan Wang, Lizhu Han, Bian Yuan
Affiliations
- Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Vascular Surgery Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Abstract
The emergence of COVID-19 has been associated with an increased risk of arteriovenous thrombosis, with immune inflammation playing a significant role in the pathogenesis of thrombosis. Numerous drug-related clinical trials have been undertaken to prevent thrombosis, and guidelines for its prevention and treatment are continuously evolving as our understanding of the disease progresses. This article provides a comprehensive review of the mechanisms underlying thrombosis in COVID-19 patients, as well as the advancements in clinical trials and guidelines for thrombosis prevention with pharmacological interventions.
MeSH
Vaccines, Covid-19, Thrombosis